Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.

ABSTRACT:

Background

Maintenance therapy with 13-cis-retinoic acid and immunotherapy (given after completion of intensive cytotoxic therapy) improves outcome for high-risk neuroblastoma patients. The synthetic retinoid fenretinide (4-HPR) achieved multiple complete responses in relapse/refractory neuroblastoma in early-phase clinical trials, has low systemic toxicity, and has been considered for maintenance therapy clinical trials. Difluoromethylornithine (DFMO, an irreversible inhibitor of ornithine decarboxylase with minimal single-agent clinical response data) is being used for maintenance therapy of neuroblastoma. We evaluated the cytotoxic activity of DFMO and fenretinide in neuroblastoma cell lines.

Procedure

We tested 16 neuroblastoma cell lines in bone marrow-level hypoxia (5%

SUBMITTER: Makena MR 

PROVIDER: S-EPMC9621602 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature